Assembly Biosciences (ASMB) Stock Analysis & AI Equity Report
Assembly Biosciences (ASMB) overview
Assembly Biosciences (ASMB) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 72.3m and operating profit of USD -12.1m; the year-end share price was 34.01 USD and market capitalisation was USD 539m. Assembly Biosciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Assembly Biosciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Assembly Biosciences
Assembly Biosciences develops investigational therapies for serious viral diseases. Its clinical and research programs include long-acting helicase-primase inhibitors for recurrent genital herpes, an oral hepatitis delta virus entry inhibitor, a next-generation hepatitis B virus capsid assembly modulator, and an oral polymerase inhibitor for transplant-associated herpesviruses. The company also conducts research into additional antiviral targets and collaborates with Gilead on its herpes program.
Generate the Assembly Biosciences report
Assembly Biosciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Assembly Biosciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Assembly Biosciences
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.